Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.

The FTSE 100 index closed up 55.93 points, 0.6%, at 8,772.38. The FTSE 250 ended up 30.43 points, 0.1%, at 21,028.01, and the AIM All-Share closed up 1.84 points, 0.3%, at 746.68.

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Danaher Corp on Thursday said it has entered a partnership with AstraZeneca PLC to develop and commercialise tools and tests for precision medicine treatments, including artificial intelligence ...

Traditionally within the purview of rheumatology, gout can appropriately be managed by nephrologists for patients with ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, technological advancements, widespread smartphone usage, ...

After years of U.S. stock-market gains, investment experts see more value abroad. One recommendation: 15% to 20% in foreign ...

Among the diagnostic tools available, Positron Emission Tomography (PET) scans emerged as the leading segment in 2023, accounting for a 34.6% revenue share. PET imaging enables clinicians to detect ...

An undergraduate economics student who was born in South Sudan and raised in a refugee camp in Kenya. A graduate of a ...